Whether the primary endpoint will survive FDA scrutiny from scientific-advice

Situation

The desk packet is scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module. RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences FDA Response and Labeling file.

Decision

RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• Authorize Proceed under protocol now; scientific-advice briefing book already has the discriminator after a CMO 483 that maps to the NDA CMC module.
• Keep Pause the pathway in force until scientific-advice briefing book is completed after a CMO 483 that maps to the NDA CMC module for RWE evidence-strategy director.
• Treat scientific-advice briefing book as Escalate safety review because both readings appear after a CMO 483 that maps to the NDA CMC module.
• Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the page the primary endpoint will turns on in scientific-advice briefing book.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will.
• Check whether scientific-advice briefing book supports the labeled claim RWE evidence-strategy director would keep.
• For this Pharma & Life Sciences FDA Response and Labeling file, read scientific-advice briefing book against a CMO 483 that maps to the NDA CMC module and write the one fact that would move the primary endpoint will for RWE evidence-strategy director.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study.